Canakinumab (Ilaris®) has not been endorsed for use within NHS Wales for the treatment of adults, adolescents and children aged 4 years and older with Cryopyrin-Associated Periodic Syndromes (CAPS). The holder of the marketing authorisation is not in a position to progress a submission to AWMSG for the appraisal of canakinumab (Ilaris®) for the above indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services.